Circulating Peptidome to Indicate the Tumor-resident Proteolysis

Zaian Deng, Yaojun Li, Jia Fan, Guohui Wang, Yan Li, Yaou Zhang, Guoping Cai, Haifa Shen, Mauro Ferrari, Ye Hu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Tumor-resident proteases (TRPs) are regarded as informative biomarkers for staging cancer progression and evaluating therapeutic efficacy. Currently in the clinic, measurement of TRP is dependent on invasive biopsies, limiting their usefulness as monitoring tools. Here we identified circulating peptides naturally produced by TRPs, and evaluated their potential to monitor the efficacy of anti-tumor treatments. We established a mouse model for ovarian cancer development and treatment by orthotopic implantation of the human drug-resistant ovarian cancer cell line HeyA8-MDR, followed by porous silicon particle- or multistage vector (MSV) - enabled EphA2 siRNA therapy. Immunohistochemistry staining of tumor tissue revealed decreased expression of matrix metallopeptidase 9 (MMP-9) in mice exhibiting positive responses to MSV-EphA2 siRNA treatment. We demonstrated, via an ex vivo proteolysis assay, that C3f peptides can act as substrates of MMP-9, which cleaves C3f at L1311-L1312 into two peptides (SSATTFRL and LWENGNLLR). Importantly, we showed that these two C3f-derived fragments detected in serum were primarily generated by tumor-resident, but not blood-circulating, MMP-9. Our results suggested that the presence of the circulating fragments specially derived from the localized cleavage in tumor microenvironment can be used to evaluate therapeutic efficacy of anti-cancer treatment, assessed through a relatively noninvasive and user-friendly proteomics approach.

Original languageEnglish (US)
Article number9327
JournalScientific Reports
Volume5
DOIs
StatePublished - Mar 19 2015
Externally publishedYes

Fingerprint

Proteolysis
Metalloproteases
Neoplasms
Peptide Hydrolases
Ovarian Neoplasms
Peptides
Small Interfering RNA
Therapeutics
Tumor Microenvironment
Neoplasm Staging
Silicon
Tumor Biomarkers
Proteomics
Immunohistochemistry
Staining and Labeling
Biopsy
Cell Line
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • General

Cite this

Circulating Peptidome to Indicate the Tumor-resident Proteolysis. / Deng, Zaian; Li, Yaojun; Fan, Jia; Wang, Guohui; Li, Yan; Zhang, Yaou; Cai, Guoping; Shen, Haifa; Ferrari, Mauro; Hu, Ye.

In: Scientific Reports, Vol. 5, 9327, 19.03.2015.

Research output: Contribution to journalArticle

Deng, Z, Li, Y, Fan, J, Wang, G, Li, Y, Zhang, Y, Cai, G, Shen, H, Ferrari, M & Hu, Y 2015, 'Circulating Peptidome to Indicate the Tumor-resident Proteolysis', Scientific Reports, vol. 5, 9327. https://doi.org/10.1038/srep09327
Deng, Zaian ; Li, Yaojun ; Fan, Jia ; Wang, Guohui ; Li, Yan ; Zhang, Yaou ; Cai, Guoping ; Shen, Haifa ; Ferrari, Mauro ; Hu, Ye. / Circulating Peptidome to Indicate the Tumor-resident Proteolysis. In: Scientific Reports. 2015 ; Vol. 5.
@article{2fa53c7d059540a8b82d7cbb2e3e9267,
title = "Circulating Peptidome to Indicate the Tumor-resident Proteolysis",
abstract = "Tumor-resident proteases (TRPs) are regarded as informative biomarkers for staging cancer progression and evaluating therapeutic efficacy. Currently in the clinic, measurement of TRP is dependent on invasive biopsies, limiting their usefulness as monitoring tools. Here we identified circulating peptides naturally produced by TRPs, and evaluated their potential to monitor the efficacy of anti-tumor treatments. We established a mouse model for ovarian cancer development and treatment by orthotopic implantation of the human drug-resistant ovarian cancer cell line HeyA8-MDR, followed by porous silicon particle- or multistage vector (MSV) - enabled EphA2 siRNA therapy. Immunohistochemistry staining of tumor tissue revealed decreased expression of matrix metallopeptidase 9 (MMP-9) in mice exhibiting positive responses to MSV-EphA2 siRNA treatment. We demonstrated, via an ex vivo proteolysis assay, that C3f peptides can act as substrates of MMP-9, which cleaves C3f at L1311-L1312 into two peptides (SSATTFRL and LWENGNLLR). Importantly, we showed that these two C3f-derived fragments detected in serum were primarily generated by tumor-resident, but not blood-circulating, MMP-9. Our results suggested that the presence of the circulating fragments specially derived from the localized cleavage in tumor microenvironment can be used to evaluate therapeutic efficacy of anti-cancer treatment, assessed through a relatively noninvasive and user-friendly proteomics approach.",
author = "Zaian Deng and Yaojun Li and Jia Fan and Guohui Wang and Yan Li and Yaou Zhang and Guoping Cai and Haifa Shen and Mauro Ferrari and Ye Hu",
year = "2015",
month = "3",
day = "19",
doi = "10.1038/srep09327",
language = "English (US)",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Circulating Peptidome to Indicate the Tumor-resident Proteolysis

AU - Deng, Zaian

AU - Li, Yaojun

AU - Fan, Jia

AU - Wang, Guohui

AU - Li, Yan

AU - Zhang, Yaou

AU - Cai, Guoping

AU - Shen, Haifa

AU - Ferrari, Mauro

AU - Hu, Ye

PY - 2015/3/19

Y1 - 2015/3/19

N2 - Tumor-resident proteases (TRPs) are regarded as informative biomarkers for staging cancer progression and evaluating therapeutic efficacy. Currently in the clinic, measurement of TRP is dependent on invasive biopsies, limiting their usefulness as monitoring tools. Here we identified circulating peptides naturally produced by TRPs, and evaluated their potential to monitor the efficacy of anti-tumor treatments. We established a mouse model for ovarian cancer development and treatment by orthotopic implantation of the human drug-resistant ovarian cancer cell line HeyA8-MDR, followed by porous silicon particle- or multistage vector (MSV) - enabled EphA2 siRNA therapy. Immunohistochemistry staining of tumor tissue revealed decreased expression of matrix metallopeptidase 9 (MMP-9) in mice exhibiting positive responses to MSV-EphA2 siRNA treatment. We demonstrated, via an ex vivo proteolysis assay, that C3f peptides can act as substrates of MMP-9, which cleaves C3f at L1311-L1312 into two peptides (SSATTFRL and LWENGNLLR). Importantly, we showed that these two C3f-derived fragments detected in serum were primarily generated by tumor-resident, but not blood-circulating, MMP-9. Our results suggested that the presence of the circulating fragments specially derived from the localized cleavage in tumor microenvironment can be used to evaluate therapeutic efficacy of anti-cancer treatment, assessed through a relatively noninvasive and user-friendly proteomics approach.

AB - Tumor-resident proteases (TRPs) are regarded as informative biomarkers for staging cancer progression and evaluating therapeutic efficacy. Currently in the clinic, measurement of TRP is dependent on invasive biopsies, limiting their usefulness as monitoring tools. Here we identified circulating peptides naturally produced by TRPs, and evaluated their potential to monitor the efficacy of anti-tumor treatments. We established a mouse model for ovarian cancer development and treatment by orthotopic implantation of the human drug-resistant ovarian cancer cell line HeyA8-MDR, followed by porous silicon particle- or multistage vector (MSV) - enabled EphA2 siRNA therapy. Immunohistochemistry staining of tumor tissue revealed decreased expression of matrix metallopeptidase 9 (MMP-9) in mice exhibiting positive responses to MSV-EphA2 siRNA treatment. We demonstrated, via an ex vivo proteolysis assay, that C3f peptides can act as substrates of MMP-9, which cleaves C3f at L1311-L1312 into two peptides (SSATTFRL and LWENGNLLR). Importantly, we showed that these two C3f-derived fragments detected in serum were primarily generated by tumor-resident, but not blood-circulating, MMP-9. Our results suggested that the presence of the circulating fragments specially derived from the localized cleavage in tumor microenvironment can be used to evaluate therapeutic efficacy of anti-cancer treatment, assessed through a relatively noninvasive and user-friendly proteomics approach.

UR - http://www.scopus.com/inward/record.url?scp=84925423337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925423337&partnerID=8YFLogxK

U2 - 10.1038/srep09327

DO - 10.1038/srep09327

M3 - Article

C2 - 25788424

AN - SCOPUS:84925423337

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 9327

ER -